Advantage Austria Show navigation

Baxter Expands its Austrian Sites

Baxter
August 28, 2013

The pharmaceutical giant is investing in production facilities and a new logistics center 

The American pharmaceutical company Baxter is consistently expanding its business operations at its sites in Austria (Vienna and Lower Austria). Baxter currently employs a work force of 4,400 employees in Austria, and is investing more than EUR 100 million in its operating facilities in 2013. Since the year 2006 it has invested a total of EUR 600 million. 80 percent of Baxter’s bioscience product portfolio is researched, developed and/or produced in Austria. Of the 22 drugs which the company manufactures in Austria, 98 percent is exported to more than 100 countries. At present Baxter boasts 42 projects and products in its research and development pipeline.

At the present time Baxter is expanding its production facilities in Vienna and Lower Austria, which currently feature a total area of 400,000 square meters. For example, the entire production of active pharmaceutical ingredients used in the vaccination against type C meningococcal disease was transferred from the USA to Austria. The expansion of production of a biosurgery product to induce hemostasis during operations was also relocated to Austria, creating a total of about 50 new jobs. Moreover, the filling of a tissue adhesive was expanded in Austria. The company is also investing in the development of new, special injections as well as the modernization of production facilities or drugs from human albumin, an integral part of plasma. It issued in emergency medicine if a person loses a large amount of blood. A new quality control building is helping to carry out the growing number of quality control tests. Baxter is also investing EUR 50 million in a state-of-the-art logistics center scheduled to be opened in 2015, which will ensure that the required infrastructure is available.   

print
©©ADVANTAGE AUSTRIA